[Federal Register: June 17, 2010 (Volume 75, Number 116)]
[Notices]
[Page 34463-34464]
[DOCID:fr17jn10-86]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0274]

Oversight of Laboratory Developed Tests; Public Meeting; Request
for Comments

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice of public meeting; request for comments.

-----------------------------------------------------------------------

    Summary: The Food and Drug Administration (FDA) is announcing the
following public meeting: ``Oversight of Laboratory Developed Tests.''
The purpose of the public meeting is to create a forum for interested
stakeholders to discuss the agency's oversight of laboratory developed
tests (LDTs). FDA is seeking input and requesting comments on this
topic.
    Date and Time: The public meeting will be held on July 19 and 20,
2010, from 8 a.m. to 5 p.m.
    Location: The public meeting will be held at Crowne Plaza
Washington, DC - Rockville, 3 Research Court, Rockville, MD 20850. For
directions, please contact the hotel<PHONE_NUMBER> or refer to the
meeting web page at http://www.fda.gov/MedicalDevices/NewsEvents/
WorkshopsConferences/default.htm.
    Contact: Katherine Serrano, Center for Devices and Radiological
Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
66, rm. 5613, Silver Spring MD 20993-0002,<PHONE_NUMBER>, e-mail:
<EMAIL_ADDRESS>    Registration and Requests for Oral Presentations: There is no
registration fee to attend the public meeting. Registration can be
completed online at http://www.fda.gov/MedicalDevices/NewsEvents/
WorkshopsConferences/default.htm. Online registration is available
until 5 p.m. on July 12, 2010. Persons without Internet access may call
Katherine Serrano at<PHONE_NUMBER> by July 12, 2010, to register for the
meeting. Early registration is recommended because seating is limited.
If space permits, onsite registration will be permitted on a first-
come, first-served basis.
    Interested persons who would like to make a presentation during the
meeting will be given 10 minutes to do so if they submit their request
(either electronic or written) to the contact person at the address
shown in the Contact section of this document, and to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852 (including name, title,
firm name, address, telephone, and fax number). All requests should
indicate in which of the four sessions of the meeting the person would
like to present. Persons who would like to present in multiple sessions
should indicate this in their request as well as provide a
prioritization of the sessions in which they would like to present. A
copy of the material to be presented may also be submitted with
requests. Depending upon the number of individuals and organizations
that submit requests to present, the allotted time may be expanded or
shortened to provide all interested parties an opportunity to present.
Requests to present are to be identified with the docket number found
in brackets in the heading of this document.
    If you need special accommodations due to a disability, please
contact Katherine Serrano (see Contact) at least 7 days in advance of
the meeting.
    Comments: FDA is holding this public meeting to provide a public
forum in which it will hear presentations and comments from interested
stakeholders regarding reasonable and effective regulation of LDTs. The
comment period for this public meeting closes on August 15, 2010.
    Regardless of attendance at the public meeting, interested persons
may submit either electronic or written comments regarding this
document. Submit electronic comments to http://www.regulations.gov.
Submit written comments to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville MD 20852. It is only necessary to send one set of comments.
It is no longer necessary to send two copies of mailed comments.
Identify comments with the docket number found in brackets in the
heading of this document. Received comments may be seen in the Division
of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

SUPPLEMENTARY INFORMATION:

I. Background

    Since the implementation of the Medical Device Amendments of 1976,
FDA has generally exercised enforcement discretion and not enforced
applicable regulations with respect to LDTs, a class of in vitro
diagnostics that are manufactured, including being developed and
validated, and offered, within a single laboratory. Thus, FDA has not
actively regulated most LDTs.
    Initially, laboratories manufactured LDTs that were generally
relatively simple, well-understood pathology tests or that diagnosed
rare diseases and conditions that were intended to be used by
physicians and pathologists within a single institution in which both
were actively part of patient care. These tests were ordinarily either
well-characterized, low-risk diagnostics or for rare diseases for which
adequate validation would not be feasible and the tests were being used
to serve the needs of the local patient population. In addition, the
components of traditional LDTs were regulated individually by FDA as
analyte specific reagents or other specific or general reagents, and
the tests were developed and offered in laboratories with certificates
to perform high complexity tests under the Clinical Laboratory
Improvement Amendments of 1988, which are laboratories that have
extensive experience in complex laboratory testing. Today, while these
tests are still performed in laboratories with high complexity
certificates, they often use components that are not regulated
individually by FDA, and they are often used to assess high-risk but
relatively common diseases and conditions and to inform critical
treatment decisions and are often performed in geographically distant
commercial laboratories instead of within the patient's health care
setting under the supervision of a patient's pathologist and treating
physician, or may be marketed directly to consumers. In addition, even
when FDA-approved tests are available for a disease or condition,
laboratories often continue to use LDTs that have not been reviewed by
the agency. Finally, an increasing number of LDT manufacturers are
corporations rather than hospitals or public health laboratories, which
represent a significant shift in the types of tests developed and the
business model for developing them.
    At the same time as LDTs are becoming more complex, diagnostic
tests are playing an increasingly important role in clinical
decisionmaking and disease management, particularly in the context of
personalized medicine. However, LDTs that have not been properly
validated for their intended use put patients at risk. Risks include
missed diagnosis, wrong diagnosis, and failure to receive appropriate
treatment. In April of 2008, the Secretary's Advisory Committee on
Genetics, Health, and Society, in its report entitled ``U.S. System of
Oversight of Genetic Testing,'' recommended that ``FDA should address
all laboratory tests in a manner that takes advantage of its current
experience in evaluating laboratory tests.''
    FDA also recognizes that while the absence of FDA oversight may
make it

easier for laboratories to develop and offer tests on a rapid timeline,
the absence of a level playing field creates a competitive disadvantage
and potential disincentive to innovation by other manufacturers whose
tests are approved or cleared by the agency for similar indications. In
addition, as set out above, it means that some diagnostics critical for
patient care may not be developed in a manner that provides a
reasonable assurance of safety and effectiveness.
    In response to these public health concerns, the agency believes it
is time to reconsider its policy of enforcement discretion over LDTs.
The public must be assured that the tests used in the provision of
health care, whether developed by a laboratory or other manufacturer,
are safe and effective. However, The FDA recognizes that there are
issues unique to the laboratory community that should be taken into
consideration so that patients will receive the desired benefits of
innovative, yet safe and effective, diagnostic tests. FDA recognizes
the importance of implementing an oversight framework that fosters
innovation in this area while assuring that such tests are safe and
effective. For example, the field of genomics and genetic testing has
the potential to revolutionize patient care. As a second example,
fostering innovation in tests for rare diseases and conditions is
another important public health concern. In these and other categories,
it is important that FDA provide a reasonable, predictable, and
consistent regulatory policy for ensuring the safety and effectiveness
of LDTs and provide sufficient time for implementation. Therefore, this
policy should encourage innovation, improve patient outcomes,
strengthen patient confidence in the reliability of these products, and
help reduce health care costs.
    At this time, FDA believes that a risk-based application of
oversight to LDTs is the appropriate approach to achieve the desired
public health goals and would like to hear from stakeholders, including
laboratory professionals, clinicians, patients, and industry, as we
develop our draft oversight framework, to define the issues that pose
the greatest concern to the public health. The public meeting announced
in this notice will serve as a forum to discuss issues and stakeholder
concerns surrounding LDT oversight. Following the public meeting and
the close of the public docket the FDA will move forward expeditiously
to develop a draft oversight framework for public comment to provide
predictability as quickly as possible. The FDA also intends to phase in
such a framework over time based on the level of risk of the test.

II. Agenda

    FDA will start the public meeting with a series of presentations
introducing the history and current regulatory status of LDTs. The
remainder of the meeting will be divided into four sessions
highlighting areas in which FDA hopes to gain public input from
critical perspectives in response to its proposal to develop an
oversight framework, as well as to hear stakeholder opinions on which
issues around laboratory developed testing present the greatest concern
to the public health. These sessions include the following: (1) Patient
Considerations, (2) Challenges for Laboratories, (3) Direct to Consumer
Marketing of Testing, and (4) Education and Outreach. Each session will
consist of approximately 2 hours of public presentations focused on the
session topic followed by an expert panel discussion and a question-
and-answer period. This public meeting agenda will be available on the
Internet at http://www.fda.gov/MedicalDevices/NewsEvents/
WorkshopsConferences/default.htm.

III. Transcripts

    Please be advised that as soon as a transcript is available, it
will be accessible at http://www.regulations.gov. A link to the
transcripts will also be available on the Internet at http://
www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm
approximately 45 days after the meeting. The transcript may be viewed
at the Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD. A
transcript will also be available in either hardcopy or on CD-ROM,
after submission of a Freedom of Information request. Written requests
are to be sent to Division of Freedom of Information (HFI-35), Office
of Management Programs, Food and Drug Administration, 5600 Fishers
Lane, rm. 6-30, Rockville, MD 20857.

    Dated: June 11, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-14654 Filed 6-16-10; 8:45 am]
BILLING CODE 4160-01-S


[Federal Register Volume 80, Number 91 (Tuesday, May 12, 2015)]
[Notices]
[Page 27153]
[FR Doc No: 2015-11414]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. AD10-12-006]

Increasing Market and Planning Efficiency Through Improved
Software; Supplemental Agenda Notice

    Take notice that Commission staff will convene a technical
conference on June 22, 23, and 24, 2015 to discuss opportunities for
increasing real-time and day-ahead market efficiency through improved
software.
    This conference will bring together diverse experts from public
utilities, the software industry, government, research centers and
academia and is intended to build on the discussions initiated in the
previous Commission staff technical conferences on increasing market
and planning efficiency through improved software.
    The agenda for this conference is attached. If any changes occur,
the revised agenda will be posted on the calendar page for this event
on the Commission's Web site \1\ prior to the event. The technical
conference may be attended by one or more Commissioners.
---------------------------------------------------------------------------

    \1\ http://www.ferc.gov/industries/electric/indus-act/market-planning/2015-conference.asp.

    Dated: May 5, 2015.
Kimberly D. Bose,
Secretary.
[FR Doc. 2015-11414 Filed 5-11-15; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register Volume 80, Number 88 (Thursday, May 7, 2015)]
[Proposed Rules]
[Pages 26210-26212]
[FR Doc No: 2015-10629]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA-HQ-OAR-2015-0071; FRL-9926-97-OAR]
RIN 2060-AS57

Prevention of Significant Deterioration Permitting for Greenhouse
Gases: Providing Option for Rescission of EPA-Issued Tailoring Rule
Step 2 Prevention of Significant Deterioration Permits

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

-----------------------------------------------------------------------

SUMMARY: The Environmental Protection Agency (EPA) is proposing to
amend the federal Prevention of Significant Deterioration (PSD) program
regulations to allow for rescission of certain PSD permits issued by
the EPA and delegated reviewing authorities under Step 2 of the
Prevention of Significant Deterioration and Title V Greenhouse Gas
(GHG) Tailoring Rule (Tailoring Rule). We are proposing to take this
action in order to provide a mechanism for the EPA and delegated
reviewing authorities to rescind PSD permits that are no longer
required in light of the United States (U.S.) Supreme Court's decision
in Utility Air Regulatory Group (UARG) v. EPA and the amended appeals
court judgment in Coalition for Responsible Regulation (Coalition) v.
EPA, vacating that rule. These decisions determined that Step 2 of the
Tailoring

Rule was not required by the Clean Air Act (CAA or Act) and vacated the
EPA regulations implementing Step 2. When effective, this action would
authorize the EPA and delegated reviewing authorities to rescind Step 2
GHG PSD permits in response to requests from applicants who can
demonstrate that they are eligible for permit rescission. In the
``Rules and Regulations'' section of this Federal Register, we are
amending the federal PSD program regulations as a direct final rule
without a prior proposed rule. If we receive no adverse comment in
response to the direct final rule, we will not take further action on
this proposed rule.

DATES: Written comments must be received by June 8, 2015.
    Public Hearing: If anyone contacts the EPA by May 18, 2015,
requesting to speak at a public hearing on this action, the EPA will
hold a public hearing on May 22, 2015 in Research Triangle Park, North
Carolina. The EPA will not hold a hearing if one is not requested.
Please check the EPA's Web page at http://www.epa.gov/nsr on May 19,
2015 for the announcement of whether the hearing will be held.

ADDRESSES: Submit your comments, identified by Docket ID No. EPA-HQ-
OAR-2015-0071, by mail to U.S. Environmental Protection Agency, EPA
Docket Center, Mail Code 28221T, 1200 Pennsylvania Avenue NW.,
Washington, DC 20460. Comments may also be submitted electronically or
through hand delivery/courier by following the detailed instructions in
the ADDRESSES section of the direct final rule located in the rules
section of this Federal Register.

FOR FURTHER INFORMATION CONTACT: Mrs. Jessica Monta[ntilde]ez, U.S.
Environmental Protection Agency, Office of Air Quality Planning and
Standards, Air Quality Planning Division, (C504-03), Research Triangle
Park, NC 27711, telephone number<PHONE_NUMBER>, email at
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. What are the details for the potential public hearing?

    If there is a public hearing, it will be held at the EPA, Building
C, 109 T.W. Alexander Drive, Research Triangle Park, North Carolina,
27709; the room number will be announced on the NSR Web site at http://www.epa.gov/nsr. If requested, the hearing will provide interested
parties the opportunity to present data, views or arguments concerning
this action. The EPA will make every effort to accommodate all speakers
who arrive and register. Because this hearing will be held at U.S.
government facilities, individuals planning to attend the hearing
should be prepared to show valid picture identification to the security
staff in order to gain access to the meeting room. Please note that the
REAL ID Act, passed by Congress in 2005, established new requirements
for entering federal facilities. These requirements took effect July
21, 2014. If your driver's license is issued by American Samoa,
Arizona, Idaho, Louisiana, Maine, Minnesota, New Hampshire or New York,
you must present an additional form of identification to enter the
federal buildings where the public hearings will be held. Acceptable
alternative forms of identification include: federal employee badges,
passports, enhanced driver's licenses and military identification
cards. For additional information for the status of your state
regarding REAL ID, go to http://www.dhs.gov/real-id-enforcement-brief.
In addition, you will need to obtain a property pass for any personal
belongings you bring with you. Upon leaving the building, you will be
required to return this property pass to the security desk. No large
signs will be allowed in the building, cameras may only be used outside
of the building and demonstrations will not be allowed on federal
property for security reasons. If held, the public hearing will begin
at 10:00 a.m. and continue until 5:00 p.m., if necessary, depending on
the number of speakers. The EPA may end the hearing early if all
registered speakers have had an opportunity to speak, but no earlier
than 2:00 p.m. Persons wishing to present oral testimony that have not
made arrangements in advance should register by 2:00 p.m. the day of
the hearing. Oral testimony will be limited to 5 minutes per commenter.
The EPA encourages commenters to provide written versions of their oral
testimonies either electronically (on computer disk or CD-ROM) or in
paper copy. Verbatim transcripts and written statements will be
included in the rulemaking docket.
    If you want to request a hearing and present oral testimony at the
hearing, you should notify, on or before May 18, 2015, Ms. Pamela Long,
U.S. Environmental Protection Agency, Office of Air Quality Planning
and Standards, Air Quality Policy Division, C504-01, Research Triangle
Park, NC 27711, telephone<PHONE_NUMBER>, email<EMAIL_ADDRESS>The
hearing will be strictly limited to the subject matter of the proposal,
the scope of which is discussed below. Any member of the public may
file a written comment by the close of the comment period. Written
comments should be submitted to Docket ID No. EPA-HQ-OAR-2015-0071 at
the addresses given above for submittal of comments. If a hearing is
held, the hearing schedule, including the list of speakers, will be
posted on the EPA's Web page at http://www.epa.gov/nsr. A verbatim
transcript of the hearing, if held, and written comments will be made
available for copying during normal working hours at the EPA Docket
Center address given above for inspection of documents.

II. Why is the EPA issuing this proposed rule?

    The EPA is proposing to take action to amend the federal PSD
program regulation at 40 CFR 52.21 to allow existing PSD permits that
were issued under Step 2 of the Tailoring Rule \1\ for GHGs to be
rescinded. This proposed action narrowly amends the permit rescission
provisions in the federal PSD regulations found in 40 CFR 52.21(w) to
allow for the rescission of EPA-issued PSD permits \2\ that were issued
under Step 2 of the Tailoring Rule permitting regulations.
---------------------------------------------------------------------------

    \1\ Prevention of Significant Deterioration and Title V
Greenhouse Gas Tailoring Rule (75 FR 31514, June 3, 2010); 40 CFR
52.21(b)(49)(v).
    \2\ The terms ``EPA-issued PSD permits that were issued under
Step 2 of the Tailoring Rule'' and ``EPA-issued Step 2 PSD permits''
both refer to PSD permits issued by the EPA as well as by delegated
reviewing authorities under Step 2 of the Tailoring Rule.
---------------------------------------------------------------------------

    The U.S. Supreme Court determined the permitting requirements under
Step 2 of the Tailoring Rule to be invalid in UARG v. EPA, 134 S. Ct.
2427 (2014). The Supreme Court affirmed in part and reversed in part an
earlier decision of the United States Court of Appeals for the District
of Columbia Circuit (D.C. Circuit) in Coalition for Responsible
Regulation v. EPA, 684 F.3d 102 (D.C. Cir. 2012). In further
proceedings upon consideration of the Supreme Court decision, the D.C.
Circuit amended its judgment in the Coalition case. The Amended
Judgment vacated particular provisions of the EPA's regulations
implementing Step 2 of the Tailoring Rule.
    This proposed action does not itself rescind any permits; it only
proposes the regulatory mechanism through which the EPA could then
rescind, upon request of a source, an EPA-issued Step 2 PSD permit
consistent with the U.S. Supreme Court decision and the amended
judgment of the D.C. Circuit. Furthermore, we have published a direct
final rule amending these federal PSD program regulations in the
``Rules and Regulations'' section of this Federal Register because we
view this as a non-controversial amendment and anticipate

no adverse comment. We have explained our reasons for this action in
the preamble to the direct final rule.
    If we receive no adverse comment, we will not take further action
on this proposed rule. If the EPA receives adverse comment in response
to the direct final rule, we will publish a timely withdrawal in the
Federal Register informing the public that the direct final rule will
not take effect. In that case, we would address all public comments in
any subsequent final rule based on this proposed rule.
    We do not intend to institute a second comment period on this
action. Any parties interested in commenting must do so at this time.
For further information about commenting on this rule, please see the
information provided in the ADDRESSES section of this document.
    The regulatory text for the proposal is identical to that for the
direct final rule published in the ``Rules and Regulations'' section of
this Federal Register. For further supplementary information, the
detailed rationale for the proposal and the regulatory revisions, see
the direct final rule published in a separate part of this Federal
Register.
    Neither this rule or direct final rule address any issues
concerning the federal PSD permit rescission regulations at 40 CFR
52.21(w) that are not related to the Supreme Court decision in UARG v.
EPA and the amended judgment of the D.C. Circuit. The EPA is developing
a separate rulemaking action that will provide an opportunity for the
public to comment on others circumstances where 40 CFR 52.21(w) may
limit the ability to rescind PSD permits that are no longer necessary.

III. Does this action apply to me?

    The entities potentially affected by this rule include new and
modified stationary sources that were required to obtain an EPA-issued
Step 2 PSD permit under the federal PSD regulations found at 40 CFR
52.21 solely because the source or a modification of the source was
expected to emit or increase GHG emissions over the applicable
thresholds. This includes (1) sources classified as major for PSD
purposes solely on the basis of their potential GHG emissions; and (2)
sources emitting major amounts of other pollutants that experienced a
modification resulting in an increase of only greenhouse gas emission
above the applicable levels in the EPA regulations. Entities affected
by this rule may also include state or local reviewing authorities that
have been delegated federal authority to implement the federal PSD
regulations under 40 CFR 52.21(u) and that have issued Step 2 PSD
permits to sources within their jurisdiction. This rule does not
address the requirements for approval of a PSD program into a state
implementation plan (40 CFR 51.166) or the rescission of PSD permits
issued by states and local programs with such approved programs.
Stationary sources with questions on the PSD permitting obligations
arising from Step 2 PSD permits issued by state or local reviewing
authorities under the permitting programs approved into state
implementation plans should review the governing statutory provisions
and provisions in the applicable approved state or local permitting
program to determine how to address any Step 2 PSD permitting issues
and consult with the EPA as necessary.

List of Subjects in 40 CFR Part 52

    Environmental protection, Air pollution control, Carbon monoxide,
Greenhouse gases, Incorporation by reference, Intergovernmental
relations, Lead, National ambient air quality standards, New source
review, Nitrogen dioxide, Ozone, Particulate matter, Permit
rescissions, Preconstruction permitting, Sulfur oxides, Tailoring rule,
Volatile organic compounds.

    Dated: April 30, 2015.
Gina McCarthy,
Administrator.
[FR Doc. 2015-10629 Filed 5-6-15; 8:45 am]
 BILLING CODE 6560-50-P


[Federal Register Volume 82, Number 120 (Friday, June 23, 2017)]
[Notices]
[Page 28650]
[FR Doc No: 2017-13086]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings #1

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER16-905-001.
    Applicants: Comanche Solar PV, LLC.
    Description: Notice of Non-Material Change in Status of Comanche
Solar PV, LLC.
    Filed Date: 6/15/17.
    Accession Number: 20170615-5191.
    Comments Due: 5 p.m. ET 7/6/17.

    Docket Numbers: ER17-1774-000.
    Applicants: NextEra Energy Bluff Point, LLC.
    Description: Clarification to June 8, 2017 NextEra Energy Bluff
Point, LLC tariff filing.
    Filed Date: 6/15/17.
    Accession Number: 20170615-5208.
    Comments Due: 5 p.m. ET 7/6/17.

    Docket Numbers: ER17-1842-000.
    Applicants: Southwest Power Pool, Inc.
    Description: Sec.  205(d) Rate Filing: 1884R6 Westar Energy, Inc.
NITSA and NOA to be effective 9/1/2017.
    Filed Date: 6/16/17.
    Accession Number: 20170616-5022.
    Comments Due: 5 p.m. ET 7/7/17.

    Docket Numbers: ER17-1843-000.
    Applicants: Southwest Power Pool, Inc.
    Description: Sec.  205(d) Rate Filing: 1885R6 Westar Energy, Inc.
NITSA and NOA to be effective 9/1/2017.
    Filed Date: 6/16/17.
    Accession Number: 20170616-5023.
    Comments Due: 5 p.m. ET 7/7/17.

    Docket Numbers: ER17-1844-000.
    Applicants: Southwest Power Pool, Inc.
    Description: Sec.  205(d) Rate Filing: 1978R6 Westar Energy, Inc.
NITSA and NOA to be effective 9/1/2017.
    Filed Date: 6/16/17.
    Accession Number: 20170616-5024.
    Comments Due: 5 p.m. ET 7/7/17.

    Docket Numbers: ER17-1845-000.
    Applicants: Lazarus Energy Holdings, LLC.
    Description: Compliance filing: Revision to Lazarus Energy MBR
Tariff to be effective 6/15/2017.
    Filed Date: 6/16/17.
    Accession Number: 20170616-5043.
    Comments Due: 5 p.m. ET 7/7/17.

    Take notice that the Commission received the following electric
securities filings:

    Docket Numbers: ES17-36-000.
    Applicants: The United Illuminating Company.
    Description: Application of The United Illuminating Company to
issue short term securities under Section 204.
    Filed Date: 6/14/17.
    Accession Number: 20170614-5060.
    Comments Due: 5 p.m. ET 7/5/17.

    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: June 16, 2017.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2017-13086 Filed 6-22-17; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register Volume 81, Number 26 (Tuesday, February 9, 2016)]
[Notices]
[Page 6846]
[FR Doc No: 2016-02505]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Commission Staff Attendance

    The Federal Energy Regulatory Commission hereby gives notice that
members of the Commission's staff may attend the following meetings
related to the transmission planning activities of the PJM
Interconnection, L.L.C. (PJM):
    PJM Planning Committee: February 11, 2016, 9:30 a.m.-12:00 p.m.
(EST)
    PJM Transmission Expansion Advisory Committee: February 11, 2016,
11:00 a.m.-3:00 p.m. (EST)
    The above-referenced meetings will be held at:
    PJM Conference and Training Center, PJM Interconnection, 2750
Monroe Boulevard, Audubon, PA 19403.
    The above-referenced meetings are open to stakeholders. Further
information may be found at www.pjm.com.
    The discussions at the meetings described above may address matters
at issue in the following proceedings:
    Docket No. ER16-429, PJM Interconnection, L.L.C.
    Docket No. ER16-736, PJM Interconnection, L.L.C.
    Docket No. ER14-972, PJM Interconnection, L.L.C.
    Docket No. ER14-1485, PJM Interconnection, L.L.C.
    Docket Nos. ER13-1944, et al., PJM Interconnection, L.L.C., et al.
    Docket No. ER15-1344, PJM Interconnection, L.L.C.
    Docket No. ER15-1387, PJM Interconnection, L.L.C. and Potomac
Electric Power Company
    Docket No. ER15-2562, PJM Interconnection, L.L.C.
    Docket No. ER15-2563, PJM Interconnection, L.L.C.
    Docket No. EL15-18, Consolidated Edison Company of New York, Inc.
v. PJM Interconnection, L.L.C.
    Docket No. EL15-41, Essential Power Rock Springs, LLC, et al. v.
PJM Interconnection, L.L.C.
    Docket Nos. ER13-1927, et al., PJM Interconnection, L.L.C., et al.
    Docket No. ER15-2114, PJM Interconnection, L.L.C. and Transource
West Virginia, LLC
    Docket No. EL15-79, TransSource, LLC v. PJM Interconnection, L.L.C.
    Docket No. EL15-95, Delaware Public Service Commission, et al., v.
PJM Interconnection, L.L.C., et al.
    Docket No. EL15-67, Linden VFT, LLC v. PJM Interconnection, L.L.C.
    Docket No. EL05-121, PJM Interconnection, L.L.C.
    For more information, contact the following: Jonathan Fernandez;
Office of Energy Market Regulation, Federal Energy Regulatory
Commission,<PHONE_NUMBER><EMAIL_ADDRESS>and Alina
Halay; Office of Energy Market Regulation, Federal Energy Regulatory
Commission,<PHONE_NUMBER><EMAIL_ADDRESS>
    Dated: February 3, 2016.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2016-02505 Filed 2-8-16; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register Volume 77, Number 231 (Friday, November 30, 2012)]
[Notices]
[Pages 71408-71409]
[FR Doc No: 2012-28969]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings

    Take notice that the Commission has received the following Natural
Gas Pipeline Rate and Refund Report filings:

Filings Instituting Proceedings

    Docket Numbers: RP13-297-000.
    Applicants: KPC Pipeline, LLC.
    Description: KPC Name Change to be effective 11/1/2012.
    Filed Date: 11/19/12.
    Accession Number: 20121119-5102.
    Comments Due: 5 p.m. ET 12/3/12.

    Docket Numbers: RP13-298-000.
    Applicants: National Fuel Gas Supply Corporation.

    Description: Market Pooling to be effective 12/19/2012.
    Filed Date: 11/19/12.
    Accession Number: 20121119-5132.
    Comments Due: 5 p.m. ET 12/3/12.

    Docket Numbers: RP13-299-000.
    Applicants: National Fuel Gas Supply Corporation.
    Description: Storage Service Enhancements to be effective 12/19/
2012.
    Filed Date: 11/19/12.
    Accession Number: 20121119-5139.
    Comments Due: 5 p.m. ET 12/3/12.

    Docket Numbers: RP13-300-000.
    Applicants: Maritimes & Northeast Pipeline, L.L.C.
    Description: Non-Conforming Agreements to be effective 12/31/2012.
    Filed Date: 11/20/12.
    Accession Number: 20121120-5000.
    Comments Due: 5 p.m. ET 12/3/12.

    Docket Numbers: RP13-301-000.
    Applicants: Venice Gathering System, LLC.
    Description: Petition for Temporary Exemption from Certain Tariff
Provisions of Venice Gathering System, L.L.C.
    Filed Date: 11/19/12.
    Accession Number: 20121119-5186.
    Comments Due: 5 p.m. ET 12/3/12.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.

Filings in Existing Proceedings

    Docket Numbers: RP13-107-001.
    Applicants: Bison Pipeline LLC.
    Description: RP13-107-000 NAESB Compliance to be effective 12/1/
2012.
    Filed Date: 11/19/12.
    Accession Number: 20121119-5163.
    Comments Due: 5 p.m. ET 12/3/12.

    Docket Numbers: RP13-109-001.
    Applicants: ANR Pipeline Company.
    Description: RP13-109-000 NAESB Compliance to be effective 12/1/
2012.
    Filed Date: 11/19/12.
    Accession Number: 20121119-5167.
    Comments Due: 5 p.m. ET 12/3/12.

    Docket Numbers: RP13-111-001.
    Applicants: North Baja Pipeline, LLC.
    Description: RP13-111 NAESB Compliance to be effective 12/1/2012.
    Filed Date: 11/19/12.
    Accession Number: 20121119-5166.
    Comments Due: 5 p.m. ET 12/3/12.

    Docket Numbers: RP13-114-001.
    Applicants: Gas Transmission Northwest LLC.
    Description: RP13-114 NAESB Compliance to be effective 12/1/2012.
    Filed Date: 11/19/12.
    Accession Number: 20121119-5170.
    Comments Due: 5 p.m. ET 12/3/12.
    Any person desiring to protest in any the above proceedings must
file in accordance with Rule 211 of the Commission's Regulations (18
CFR 385.211) on or before 5:00 p.m. Eastern time on the specified
comment date.
    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, and service can be found at:
http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other
information, call<PHONE_NUMBER> (toll free). For TTY, call (202) 502-
8659.

    Dated November 20, 2012.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2012-28969 Filed 11-29-12; 8:45 am]
BILLING CODE 6717-01-P